6496 Stock Overview
Develops and sells pharmaceutical products in Taiwan, China, and internationally. More details
| Snowflake Score | |
|---|---|
| Valuation | 2/6 |
| Future Growth | 0/6 |
| Past Performance | 0/6 |
| Financial Health | 3/6 |
| Dividends | 0/6 |
Excelsior Biopharma Inc. Competitors
Price History & Performance
| Historical stock prices | |
|---|---|
| Current Share Price | NT$29.60 |
| 52 Week High | NT$40.15 |
| 52 Week Low | NT$26.70 |
| Beta | 0.31 |
| 11 Month Change | -1.66% |
| 3 Month Change | -4.52% |
| 1 Year Change | 4.41% |
| 33 Year Change | 2.96% |
| 5 Year Change | -23.51% |
| Change since IPO | -56.08% |
Recent News & Updates
Recent updates
Be Wary Of Excelsior Biopharma (GTSM:6496) And Its Returns On Capital
Apr 01
Is Excelsior Biopharma Inc. (GTSM:6496) An Attractive Dividend Stock?
Mar 11Is Excelsior Biopharma (GTSM:6496) Using Too Much Debt?
Feb 09Are Poor Financial Prospects Dragging Down Excelsior Biopharma Inc. (GTSM:6496 Stock?
Jan 11
Our Take On The Returns On Capital At Excelsior Biopharma (GTSM:6496)
Dec 22Here's Why Excelsior Biopharma's (GTSM:6496) Statutory Earnings Are Arguably Too Conservative
Nov 30Shareholder Returns
| 6496 | TW Healthcare | TW Market | |
|---|---|---|---|
| 7D | 0.2% | 0.9% | 0.8% |
| 1Y | 4.4% | -9.1% | 30.3% |
Return vs Industry: 6496 exceeded the TW Healthcare industry which returned -9.1% over the past year.
Return vs Market: 6496 underperformed the TW Market which returned 30.3% over the past year.
Price Volatility
| 6496 volatility | |
|---|---|
| 6496 Average Weekly Movement | 2.7% |
| Healthcare Industry Average Movement | 4.2% |
| Market Average Movement | 4.6% |
| 10% most volatile stocks in TW Market | 8.0% |
| 10% least volatile stocks in TW Market | 2.1% |
Stable Share Price: 6496 has not had significant price volatility in the past 3 months compared to the TW market.
Volatility Over Time: 6496's weekly volatility (3%) has been stable over the past year.
About the Company
| Founded | Employees | CEO | Website |
|---|---|---|---|
| 1988 | n/a | Joseph Chen | www.excelsiorgroup.com.tw |
Excelsior Biopharma Inc. develops and sells pharmaceutical products in Taiwan, China, and internationally. It offers prescription drugs, over-the-counter drugs, medical devices, healthcare food products, medical supplies, and other products. The company provides its products for the therapeutic areas, such as pediatrics, gastroenterology, neurology, cardiology, dermatology, medical toxicology, dentistry, obstetrics, oncology, hematology, and otorhinolaryngology, as well as infectious diseases.
Excelsior Biopharma Inc. Fundamentals Summary
| 6496 fundamental statistics | |
|---|---|
| Market cap | NT$1.39b |
| Earnings (TTM) | -NT$70.69m |
| Revenue (TTM) | NT$830.35m |
1.7x
P/S Ratio-19.7x
P/E RatioIs 6496 overvalued?
See Fair Value and valuation analysisEarnings & Revenue
| 6496 income statement (TTM) | |
|---|---|
| Revenue | NT$830.35m |
| Cost of Revenue | NT$452.67m |
| Gross Profit | NT$377.68m |
| Other Expenses | NT$448.36m |
| Earnings | -NT$70.69m |
Last Reported Earnings
Sep 30, 2024
Next Earnings Date
n/a
| Earnings per share (EPS) | -1.51 |
| Gross Margin | 45.48% |
| Net Profit Margin | -8.51% |
| Debt/Equity Ratio | 10.8% |
How did 6496 perform over the long term?
See historical performance and comparison